NCT03601442: CTL019 Out of Specification MAP for ALL or DLBCL Patients |
|
|
| Available | N/A | | Canada, US, RoW | CTL019, tisagenlecleucel, Kymriah | Novartis Pharmaceuticals | Acute Lymphoblastic Leukemia (ALL), Diffuse Large B-cell Lymphoma (DLBCL) | | | | |
NCT01351545: A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs) |
|
|
| Recruiting | N/A | 99999 | US | A multicenter access and distribution protocol for unlicensed cryopreserved cord blood units (CBUs) | Center for International Blood and Marrow Transplant Research, National Marrow Donor Program | Hematologic Malignancies, Inherited Disorders of Metabolism, Inherited Abnormalities of Platelets, Histiocytic Disorders, Acute Myelogenous Leukemia (AML or ANLL), Acute Lymphoblastic Leukemia (ALL), Other Acute Leukemia, Chronic Myelogenous Leukemia (CML), Myelodysplastic (MDS) / Myeloproliferative (MPN) Diseases, Other Leukemia, Hodgkin Lymphoma, Non-hodgkin Lymphoma, Multiple Myeloma/ Plasma Cell Disorder (PCD), Inherited Abnormalities of Erythrocyte Differentiation or Function, Disorders of the Immune System, Autoimmune Diseases, Severe Aplastic Anemia | 10/41 | 10/41 | | |
